REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/06/2026
Back to search
Official data from USPTO
AKZYSA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
07/06/2026
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
11/09/2020
Registration date
07/06/2021
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/06/2021
Last transaction
07/06/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
FOSDICK, GEOFFREY A
Law office
M20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Sandoz AG
NOVARTIS AG
Representatives
Maury M. Tepper, III Tepper & Eyster, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Publications
History of USPTO decisions and trademark events.
33 publications found
CHLD
CHANGE OF OWNER RECEIVED FROM IB
01/19/2024
FINV
FINAL DECISION TRANSACTION PROCESSED BY IB
11/15/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/25/2021
FIMP
FINAL DISPOSITION PROCESSED
10/25/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/06/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
07/06/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/20/2021
PUBO
PUBLISHED FOR OPPOSITION
04/20/2021
GPNX
NOTIFICATION PROCESSED BY IB
04/19/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/31/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/31/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/31/2021
RFNT
REFUSAL PROCESSED BY IB
03/22/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/12/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/11/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/11/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/04/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/04/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/04/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/04/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/04/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/04/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/02/2021
RFRR
REFUSAL PROCESSED BY MPU
03/02/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/24/2021
CNRT
NON-FINAL ACTION WRITTEN
02/23/2021
DOCK
ASSIGNED TO EXAMINER
02/23/2021
MAFR
APPLICATION FILING RECEIPT MAILED
01/19/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/14/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
01/13/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/31/2020
Continuous trademark protection
Get notified about every new filing that threatens AKZYSA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.